The Change of Serum Interleukin-2 and Interleukin-12p40 in Patients with Grave’s Disease after Treatment with 131I and Its Significance_West China Medical Journal

Authors：

ZHONG Li ¹ , CHEN Qiu ² , YANG Tingqiang ³

1. Department of Endocrinology and Metabolism, the First People’s Hospital of Longquanyi District, Chengdu, Sichuan 610100, P. R. China; 2. Department of Endocrinology, University of Chinese Traditional Medicine, Chengdu, Sichuan 611130, P. R. China; 3. Department of Endocrinology, the People’s Hospital of Xinjin, Xinjin, Sichuan 611400, R. R. China;

Corresponding author：

Keywords：

Grave病; 白细胞介素-2; 白细胞介素-12p40; 自身免疫

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

目的　探讨Grave病患者采用131I治疗前后血清中白细胞介素-2（IL-2）及白细胞介素-12 p40（IL-12p40）含量的改变及细胞因子在该疾病中的作用与意义。方法　采用酶联免疫吸附试验双抗夹心法、放射免疫法，对2009年10月－2011年12月收治的28例Grave病患者（治疗组）经131I治疗前后血清中IL-2和IL-12p40含量进行自身对比及与健康志愿者（对照组）对比；同时对治疗组患者治疗前、后的血清游离三碘甲腺原氨酸（FT3）、血清游离甲状腺素（FT4）、促甲状腺激素（TSH）水平与对照组进行对比。结果　治疗后患者血清中IL-2和IL-12p40的水平为（19.54 ± 11.17）、（615.88 ± 349.32） ng/mL，明显高于治疗前（P＜0.05），且与对照组比较差异无统计学意义（P＞0.05）；患者治疗前后血清中IL-2和IL-12p40水平与FT3、FT4水平有显著相关性。结论　血清IL-2和
IL-12p40可能共同参与Grave病的发病过程，并且这两种因子的水平与FT3、FT4水平呈负相关性。

Citation： ZHONG Li,CHEN Qiu,YANG Tingqiang. The Change of Serum Interleukin-2 and Interleukin-12p40 in Patients with Grave’s Disease after Treatment with 131I and Its Significance. West China Medical Journal, 2012, 27(9): 1335-1337. doi: Copy

1.	Zhang NY, Zhao BQ, Nan Y, et al. Changes of thyroid function before and after metabolic control in diabetics[J]. Fourth Mil Med University, 1998, 19(3): 302-304.
2.	Molnar I. The balance shift in Thl/Th2 related IL-12/IL-5 eytokines in Graves’disease dufng methimazole therapy[J]. Autoimmunity, 2007, 40(1): 31-37．.
3.	Natt N, Bahn RS. Cytokinesintheevolution gravesophthalmopathy[J]. Autoimmunity, 1997, 26(2): 129-136.
4.	杨吉生, 薛兰芳, 胡明造, 等. Graves病碘-131治疗的剂量计算[J]. 云南医药, 1996, 17(1): 2-4.
5.	杨吉生, 王强, 胡明造, 等. 131I治疗Graves病的最适剂量探讨[J]. 同位素, 2000, 12(3): 177-181.
6.	Brent GA. Graves’ disease[J]. N Engl J Med, 2008, 358: 2594-605.
7.	InoueA, Koizumi S, MatsudaA, et al. Graves’hyperthyroidism showing transient hypothyroidism during interferon therapy for chronichepatitis type C[J]. Endocr, 2005, 52(3): 293-298.
8.	Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive Immunity[J]. Nat Rev Immunol, 2003, 3: 133-46.
9.	池沛冬, 李丽, 范艳莹, 等. IL-12恢复并促进氟尿嘧啶抑制的T细胞免疫功能[J]. 癌症, 2007, 26(8): 801-808.
10.	谢建平, 吴成秀, 严宗逊, 等. Graves病治疗前后细胞因子水平的变化[J]. 中华核医学杂志, 2004, 24(4): 247-249.
11.	朱明风, 温赤君, 钱红. 131I治疗Graves病的转归与三种细胞因子的关系[J].标记免疫分析与临床, 2007, 14(3): 150-152.
12.	ColinIM, Isaac J, Dupret P, et al. Adenovirus-mediated interleukin-12 gene,transfer combined with cytosine deaminase followed by 5-fluorocytosine treatment exerts potent antitumor activity in penca tumor-bearing mice BMC[J] . Cancer, 2005, 5: 51.
13.	Salvi M, Pedrazzoni M, Girasole G, et al. Serum concentrations of proinflammatory cytokines in Graves’disease: effectof treatment, thyroid function, ophthalmopathy and cigarette smoking[J]. Eur Endocrinol, 2000, 143(2): 197-202.
14.	InoueA, Koizumi S, Matsuda A, et al. Graves’hyperthyroidism showing transient hypothyroidism during interferon therapy for chronichepatitis type C[J]. Endocr, 2005, 52(3): 293-298.
15.	梁驰, 何凤屏, 曾建业, 等. Grave’s病患者血清中IFN-γ、TNF-α和IL-6的变化[J]. 广西医学, 2008, 30(8): 1146-1147.
16.	何长武, 黄莺, 王社教. 甲亢患者131碘治疗前后细胞因子水平的变化分析[J]. 陕西医学杂志, 2011, 40(11): 1493-1494.
17.	汤建林, 李玉莹, 高柳艳, 等. 131I治疗Graves病疗效评价[J]. 医学理论与实践, 2011, 24(13): 1551-1552.
18.	李春北. IL-2与IL-10浓度变化对Graves病治疗效果的预测[J]. 重庆医科大学学报, 2010, 3(3): 412-414.

1. 　Zhang NY, Zhao BQ, Nan Y, et al. Changes of thyroid function before and after metabolic control in diabetics[J]. Fourth Mil Med University, 1998, 19(3): 302-304.
2. 　Molnar I. The balance shift in Thl/Th2 related IL-12/IL-5 eytokines in Graves’disease dufng methimazole therapy[J]. Autoimmunity, 2007, 40(1): 31-37．.
3. 　Natt N, Bahn RS. Cytokinesintheevolution gravesophthalmopathy[J]. Autoimmunity, 1997, 26(2): 129-136.
4. 　杨吉生, 薛兰芳, 胡明造, 等. Graves病碘-131治疗的剂量计算[J]. 云南医药, 1996, 17(1): 2-4.
5. 　杨吉生, 王强, 胡明造, 等. 131I治疗Graves病的最适剂量探讨[J]. 同位素, 2000, 12(3): 177-181.
6. 　Brent GA. Graves’ disease[J]. N Engl J Med, 2008, 358: 2594-605.
7. 　InoueA, Koizumi S, MatsudaA, et al. Graves’hyperthyroidism showing transient hypothyroidism during interferon therapy for chronichepatitis type C[J]. Endocr, 2005, 52(3): 293-298.
8. 　Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive Immunity[J]. Nat Rev Immunol, 2003, 3: 133-46.
9. 　池沛冬, 李丽, 范艳莹, 等. IL-12恢复并促进氟尿嘧啶抑制的T细胞免疫功能[J]. 癌症, 2007, 26(8): 801-808.
10. 　谢建平, 吴成秀, 严宗逊, 等. Graves病治疗前后细胞因子水平的变化[J]. 中华核医学杂志, 2004, 24(4): 247-249.
11. 　朱明风, 温赤君, 钱红. 131I治疗Graves病的转归与三种细胞因子的关系[J].标记免疫分析与临床, 2007, 14(3): 150-152.
12. 　ColinIM, Isaac J, Dupret P, et al. Adenovirus-mediated interleukin-12 gene,transfer combined with cytosine deaminase followed by 5-fluorocytosine treatment exerts potent antitumor activity in penca tumor-bearing mice BMC[J] . Cancer, 2005, 5: 51.
13. 　Salvi M, Pedrazzoni M, Girasole G, et al. Serum concentrations of proinflammatory cytokines in Graves’disease: effectof treatment, thyroid function, ophthalmopathy and cigarette smoking[J]. Eur Endocrinol, 2000, 143(2): 197-202.
14. 　InoueA, Koizumi S, Matsuda A, et al. Graves’hyperthyroidism showing transient hypothyroidism during interferon therapy for chronichepatitis type C[J]. Endocr, 2005, 52(3): 293-298.
15. 　梁驰, 何凤屏, 曾建业, 等. Grave’s病患者血清中IFN-γ、TNF-α和IL-6的变化[J]. 广西医学, 2008, 30(8): 1146-1147.
16. 　何长武, 黄莺, 王社教. 甲亢患者131碘治疗前后细胞因子水平的变化分析[J]. 陕西医学杂志, 2011, 40(11): 1493-1494.
17. 　汤建林, 李玉莹, 高柳艳, 等. 131I治疗Graves病疗效评价[J]. 医学理论与实践, 2011, 24(13): 1551-1552.
18. 　李春北. IL-2与IL-10浓度变化对Graves病治疗效果的预测[J]. 重庆医科大学学报, 2010, 3(3): 412-414.

West China Medical Journal

The Change of Serum Interleukin-2 and Interleukin-12p40 in Patients with Grave’s Disease after Treatment with 131I and Its Significance

Abstract Full text Figures/Tables Video References Cited by

Format

Content